联环药业：美阿沙坦钾片获得药品注册证书

Group 1 - The core point of the article is that Lianhuan Pharmaceutical (600513) announced the approval of its subsidiary Changle Pharmaceutical's drug, Benazepril Potassium Tablets, by the National Medical Products Administration, which can be used for the treatment of primary hypertension in adults [1] Group 2 - The drug Benazepril Potassium Tablets has received a drug registration certificate, indicating its compliance with regulatory standards [1] - This approval may enhance the company's product portfolio and market presence in the hypertension treatment segment [1] - The approval reflects the ongoing efforts of the company to expand its pharmaceutical offerings and address health issues related to hypertension [1]